ARTICLE | Company News
Ability Pharmaceuticals, SciClone deal
May 23, 2016 7:00 AM UTC
Ability granted SciClone exclusive rights to develop and commercialize ABTL0812 in Taiwan, Vietnam and China, including Hong Kong and Macau. Ability will receive up to $20 million, which includes an ...